Neurotech International Limited (ASX: NTI) - Share Price
- Current share price for NTI : $0.013
Neurotech International Limited (NTI) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a clinical-stage biopharmaceutical development company focused on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164.
NTI General Information +
| ASX Code | NTI |
| Website | http://www.neurotechinternational.com |
| Industry/Sector | Health Care Equipment |
| Market Cap ($M) | 21 |
| NTI Share Price | $0.013 |
| Day High | $0.013 |
| Day Low | $0.013 |
| Last Close | $0.013 |
| NTI Share Price Movement | - ( No change ) |
Prices as at 16:40, 2 Sep 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Neurotech International Limited (NTI) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Neurotech International Limited (NTI) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Neurotech International Limited (NTI) price-sensitive announcements
NTI - Appendix 4E & Annual Report to shareholders
Neurotech International Limited's 2026 Annual Report highlights its focus on developing NT
Neurotech International Limited (NTI)
26 Aug 2026 | 5:19 PM
26 Aug 2026 | 5:19 PM
NTI - Receipt of Binding Commitments for $4.5m Placement
Neurotech International Limited (ASX: NTI) announced that it has secured approximately $4.
Neurotech International Limited (NTI)
4 Aug 2026 | 9:26 AM
4 Aug 2026 | 9:26 AM
NTI - Quarterly Activities/Appendix 4C Cash Flow Report
Neurotech International Limited, a clinical-stage biopharmaceutical company, released its
Neurotech International Limited (NTI)
31 Jul 2026 | 10:59 AM
31 Jul 2026 | 10:59 AM
NTI - Trading Halt
Neurotech International Limited (ASX: NTI) has requested a trading halt on its securities,
Neurotech International Limited (NTI)
31 Jul 2026 | 9:22 AM
31 Jul 2026 | 9:22 AM
Neurotech International Limited (NTI) Recent ASX Announcements
NTI Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026A | -$6.54 | -$0.60 | -46.10% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$10.60 | -$1.00 | 82.10% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$5.07 | -$0.60 | -42.90% | 0.00 | 0.00 | 0.00% | 0.0% |
NTI Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | ||
| Cochlear Limited (COH) | $8,786M | -0.3136 | 0.2540 | 0.0785 | 32.7085 | 26.0833 | 24.1850 | 2.57% | 2.67% | 2.90% |
| Fisher & Paykel Healthcare Corporation Limited (FPH) | $21,471M | 0.1388 | 0.1636 | 0.1748 | 55.1943 | 47.4334 | 40.3761 | 1.19% | 1.28% | 1.45% |
| Neurotech International Limited (NTI) | $21M | -0.4608 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| ResMed Inc. (RMD) | $19,627M | 9.5922 | 0.0984 | 0.0886 | 21.5505 | 19.6193 | 18.0224 | 1.08% | 1.17% | 1.27% |
NTI Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 26.00 | 0.00 |
| Market | 0.38 | 13.40 | 1.16 | 0.81 |
| Sector | 0.62 | 20.60 | 1.91 | 2.69 |
NTI Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Anthony Filippis | Chief Executive Officer, Managing Director | 1 Feb 2025 |
| Mr Mark Davies | Executive Chairman, Executive Director | 16 Apr 2019 |
| Mr Robert (Max) Maxwell Johnston | Non-Executive Director | 19 Apr 2024 |
| Mr Gerald Quigley | Non-Executive Director, Director of Public Relations | 7 Jul 2022 |
Neurotech International Limited (NTI) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 30 Mar 2026 | JOHNSTON, Robert (Max) | Issued | Indirect Shares | 3,571,428 | $0.014 | $49,999.990 |
| 30 Mar 2026 | DAVIES, Mark | Issued | Indirect Shares | 7,142,858 | $0.014 | $100,000.010 |
| 30 Mar 2026 | QUIGLEY, Gerald | Issued | Indirect Shares | 3,571,428 | $0.014 | $49,999.990 |
See all changes in directors' interest & trades for Neurotech International Limited (NTI) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
NTI Management
| Name | Position |
|---|---|
| Alessandra Gauvin | Company Secretary |
NTI Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Neurotech International Limited (NTI). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 94,341,233 (9.11%) | Dutch Ink Pty Ltd |
| 60,697,522 (5.78%) | Maybank Securities Pte. Ltd |
| 54,987,203 (5.40%) | Biotech Capital Management Pty Ltd |
| 53,099,919 (5.10%) | Merchant Funds Management Pty Ltd |
NTI Calendar of Events
| Date | Event |
|---|---|
| 25 August 2027 | Report (Annual) |
| 25 August 2027 | Report (Prelim) |
| 25 February 2027 | Report (Interim) |
| 15 October 2026 | Report (Annual) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
